QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)

Novartis - NVS Stock Forecast, Price & News

$92.00
+0.42 (+0.46%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$91.65
$92.19
50-Day Range
$80.03
$92.81
52-Week Range
$74.09
$94.26
Volume
1.69 million shs
Average Volume
2.29 million shs
Market Capitalization
$203.56 billion
P/E Ratio
29.02
Dividend Yield
2.47%
Price Target
$82.63

Novartis MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
10.2% Downside
$82.63 Price Target
Short Interest
Healthy
0.32% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.40mentions of Novartis in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.50%
From $6.53 to $7.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

684th out of 1,004 stocks

Pharmaceutical Preparations Industry

337th out of 489 stocks


NVS stock logo

About Novartis (NYSE:NVS) Stock

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Stock News Headlines

Why Novartis (NVS) is a Great Dividend Stock Right Now
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Brokerages Set Novartis AG (NYSE:NVS) PT at $81.40
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Novartis (NVS) Could Be a Great Choice
Here's Why Novartis (NVS) is a Strong Value Stock
NVS vs. LLY: Which Stock Is the Better Value Option?
2 Stable Stocks You Can Buy Now for Under $100
Novartis AG (NYSE:NVS) Q4 2022 Earnings Call Transcript
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
Top Stock Reports for NIKE, Novartis & Wells Fargo
Check Out What Whales Are Doing With NVS
Novartis' (NVS) PNH Candidate Achieves Study Objectives
Novartis: Phase III PSMAfore Study With Pluvicto Meets Primary Endpoint
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Company Calendar

Last Earnings
2/01/2023
Ex-Dividend for 3/20 Dividend
3/09/2023
Dividend Payable
3/20/2023
Today
3/31/2023
Next Earnings (Estimated)
4/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
101,703
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$82.63
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
-10.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
12 Analysts

Profitability

Net Income
$6.96 billion
Pretax Margin
16.15%

Debt

Sales & Book Value

Annual Sales
$50.55 billion
Cash Flow
$6.10 per share
Book Value
$26.86 per share

Miscellaneous

Outstanding Shares
2,212,600,000
Free Float
2,212,379,000
Market Cap
$203.56 billion
Optionable
Optionable
Beta
0.52

Social Links


Key Executives

  • Vasant Narasimhan
    Chief Executive Officer
  • Steffen Lang
    President-Operations
  • Harry Werner Kirsch
    Chief Financial Officer
  • Shreeram Aradhye
    Chief Medical Officer
  • Klaus Moosmayer
    Chief Ethics, Risk & Compliance Officer













NVS Stock - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price forecast for 2023?

12 analysts have issued 12 month target prices for Novartis' shares. Their NVS share price forecasts range from $70.00 to $90.00. On average, they predict the company's stock price to reach $82.63 in the next year. This suggests that the stock has a possible downside of 10.2%.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How have NVS shares performed in 2023?

Novartis' stock was trading at $90.72 at the start of the year. Since then, NVS shares have increased by 1.4% and is now trading at $92.00.
View the best growth stocks for 2023 here
.

Are investors shorting Novartis?

Novartis saw a increase in short interest in February. As of February 15th, there was short interest totaling 6,440,000 shares, an increase of 16.9% from the January 31st total of 5,510,000 shares. Based on an average daily volume of 1,940,000 shares, the short-interest ratio is presently 3.3 days. Approximately 0.3% of the company's stock are short sold.
View Novartis' Short Interest
.

When is Novartis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our NVS earnings forecast
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) released its earnings results on Wednesday, February, 1st. The company reported $1.51 EPS for the quarter, topping the consensus estimate of $1.42 by $0.09. The business had revenue of $12.69 billion for the quarter, compared to the consensus estimate of $12.85 billion. Novartis had a trailing twelve-month return on equity of 21.79% and a net margin of 13.75%.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Thursday, February 2nd. Shareholders of record on Friday, March 10th will be paid a dividend of $3.4694 per share on Monday, March 20th. This represents a dividend yield of 2.6%. The ex-dividend date is Thursday, March 9th. This is a positive change from the stock's previous annual dividend of $1.18.
Read our dividend analysis for NVS
.

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.27 per share and currently has a dividend yield of 2.50%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 71.61%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 32.34% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by many different retail and institutional investors. Top institutional investors include Franklin Resources Inc. (0.30%), Morgan Stanley (0.29%), Bank of America Corp DE (0.29%), Dimensional Fund Advisors LP (0.27%), Charles Schwab Investment Management Inc. (0.21%) and Moneta Group Investment Advisors LLC (0.20%).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $92.00.

How much money does Novartis make?

Novartis (NYSE:NVS) has a market capitalization of $203.56 billion and generates $50.55 billion in revenue each year. The company earns $6.96 billion in net income (profit) each year or $3.17 on an earnings per share basis.

How many employees does Novartis have?

The company employs 101,703 workers across the globe.

Does Novartis have any subsidiaries?
The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The official website for the company is www.novartis.com. The company can be reached via phone at (161) 324-1111, via email at investor.relations@novartis.com, or via fax at 41-61-324-7826.

This page (NYSE:NVS) was last updated on 3/31/2023 by MarketBeat.com Staff